Resmed
RMD
$182.82
-1.94%
ResMed Inc. is a global leader in the healthcare sector, specifically within the Medical Instruments & Supplies industry, focused on developing and supplying medical devices and software solutions for sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. The company is a dominant market player in respiratory care, distinguished by its integrated ecosystem of cloud-connected devices, masks, and digital health platforms that enable remote patient monitoring and data-driven care. The current investor narrative revolves around the company's resilience and growth trajectory in a structurally expanding market for sleep therapy, though recent stock performance reflects investor concerns over potential competitive pressures, reimbursement changes, or broader market rotations away from healthcare staples, as evidenced by its significant year-to-date price decline.…
RMD
Resmed
$182.82
Investment Opinion: Should I buy RMD Today?
Rating & Thesis: Hold. ResMed is a fundamentally strong company caught in a severe technical and sentiment downdraft; investors should wait for evidence of a stabilization in price and revenue growth before committing new capital. The analyst consensus appears mixed but leans cautiously optimistic, with an implied average target derived from a forward EPS of $16.15.
Supporting Evidence: The stock trades at a forward PE of 15.62x, a significant discount to its trailing PE of 27.02x, implying the market expects earnings growth. Revenue grew 10.98% YoY, profitability is robust with a net margin of 27.59%, and free cash flow generation is strong at $1.79B TTM. However, the elevated Price-to-Sales ratio of 7.36x suggests the market still prices in a premium, and the stock's 22.25% YTD decline severely underperforms the market.
Risks & Conditions: The two biggest risks are continued revenue deceleration and a technical breakdown below the $190.40 support level. This Hold would upgrade to a Buy if the stock establishes a higher low above $200 and Q3 revenue growth re-accelerates above 12% YoY. It would downgrade to a Sell if revenue growth falls below 8% or the stock breaks and sustains below $185. Relative to its own compressed valuation and strong fundamentals, the stock appears fairly valued to slightly undervalued, but the negative momentum warrants caution.
Sign up to view all
RMD 12-Month Price Forecast
ResMed presents a classic 'value trap' versus 'fallen angel' dilemma. The fundamentals—high margins, strong cash flow, clean balance sheet—are undeniably attractive and support a higher valuation. However, the severe price decline, decelerating growth, and break to new lows cannot be ignored, suggesting the market sees a deterioration in the growth narrative. The neutral stance reflects this tension; the risk/reward is balanced at current levels. The stance would turn bullish on confirmation of a successful technical reversal (e.g., a weekly close above $210) and stabilization of revenue growth. It would turn bearish on a confirmed breakdown below $185 accompanied by another quarter of decelerating growth.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Resmed's 12-month outlook, with a consensus price target around $237.67 and implied upside of +30.0% versus the current price.
Average Target
$237.67
12 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
12
covering this stock
Price Range
$146 - $238
Analyst target range
ResMed is covered by 12 analysts, indicating solid institutional interest. The consensus sentiment appears mixed but leans cautiously optimistic, as evidenced by recent actions from firms like Citigroup (Buy), RBC Capital (Outperform), and Wells Fargo (Equal Weight), alongside a notable downgrade from Baird from Outperform to Neutral in mid-December. The average target price is not explicitly provided in the data, but analyst estimates point to an average EPS of $16.15 and average revenue of $7.70 billion for the forward period, which investors would use to derive implied valuation targets. The target range, inferred from estimated EPS, shows a low of $15.93 and a high of $16.27, a very tight spread of just 2.1%, which signals high analyst conviction and agreement on the company's near-term earnings power, reducing uncertainty for investors. The high target likely assumes successful execution on market share gains and margin expansion from its digital health initiatives, while the low target may factor in risks like increased competition or regulatory headwinds.
Bulls vs Bears: RMD Investment Factors
The investment debate for ResMed centers on a clash between deteriorating technical momentum and deeply oversold conditions versus a fundamentally sound, profitable business with a strong balance sheet. Currently, the bear case has stronger short-term evidence, given the stock's severe underperformance, decelerating revenue growth, and break to new lows. However, the bull case is supported by high-quality fundamentals that appear mispriced. The single most important tension is whether the current price decline represents a market overreaction creating a compelling value entry, or a justified repricing due to a fundamental slowdown in growth prospects. The resolution hinges on the next quarter's revenue growth rate and margin trajectory.
Bullish
- Strong Profitability & Expanding Margins: ResMed's net margin reached 27.59% in the latest quarter, with gross margin improving sequentially to 62.18%. This demonstrates superior pricing power and operational efficiency in the medical device sector, translating directly to robust cash generation.
- Exceptional Financial Health & Cash Flow: The company has a fortress balance sheet with a debt-to-equity ratio of only 0.14 and a current ratio of 3.44. It generated $1.79 billion in TTM free cash flow, funding a $175M buyback and dividends, underpinning shareholder returns.
- Deeply Oversold, Trading at 52-Week Low: The stock is down 22.25% YTD and trades at $190.57, just 0.09% above its 52-week low of $190.40. This extreme technical positioning, coupled with a forward PE of 15.6x, suggests significant pessimism may be priced in, creating a potential value opportunity.
- Solid Revenue Growth in Structural Market: Q2 revenue grew 10.98% YoY to $1.42B, driven by the core Sleep and Respiratory segment. The company operates in a structurally growing market for sleep apnea therapy, supported by demographic trends like aging populations.
Bearish
- Severe Negative Momentum & Underperformance: The stock has drastically underperformed the market, down 25.63% over 3 months versus the S&P 500's +10.28% gain, a relative strength of -35.91. This accelerating sell-off, despite a low beta of 0.845, indicates severe company/sector-specific selling pressure.
- Revenue Growth Shows Sequential Deceleration: While YoY revenue growth was 10.98%, this marks a slowdown from the 14.2% sequential growth seen in the prior quarter. This deceleration may fuel investor concerns about the sustainability of growth in the face of potential competition or market saturation.
- Elevated Valuation Multiples vs. Industry: ResMed trades at a trailing PE of 27.02x and a PS ratio of 7.36x, which are elevated compared to industry averages. This premium valuation leaves the stock vulnerable to multiple compression if growth expectations are not met.
- High Short Interest & Bearish Sentiment: With a short ratio of 9.7 days to cover and a recent downgrade from Baird (Outperform to Neutral), bearish positioning is significant. This creates a headwind for any recovery, as short sellers will defend their positions.
RMD Technical Analysis
The prevailing price trend for ResMed is a pronounced and sustained downtrend, with the stock down 22.25% over the past year and currently trading at $190.57, which is just 0.09% above its 52-week low of $190.40, positioning it at the absolute bottom of its annual range. This extreme positioning suggests the stock is deeply oversold and may present a value opportunity, but it also signals severe negative momentum and a lack of buyer conviction, making it a potential 'falling knife' scenario. Recent momentum has been sharply negative and accelerating, with the stock down 25.63% over the past three months and 10.08% over the past month, significantly underperforming the S&P 500, which gained 10.28% and 6.31% over the same periods, respectively, as indicated by relative strength figures of -35.91 and -16.39. This severe underperformance, coupled with a beta of 0.845 indicating lower volatility than the market, suggests the sell-off is company or sector-specific rather than a broad market move. Key technical levels are clearly defined, with immediate support at the 52-week low of $190.40 and major resistance far above at the 52-week high of $293.81; a breakdown below $190.40 could trigger further algorithmic selling and a test of multi-year lows, while any meaningful recovery would need to reclaim the $220-$230 zone that acted as support in late March. The stock's maximum drawdown of -35.12% and a short ratio of 9.7 days to cover indicate significant bearish positioning and high selling pressure that must be absorbed for a sustainable rebound.
Beta
0.84
0.84x market volatility
Max Drawdown
-37.8%
Largest decline past year
52-Week Range
$180-$294
Price range past year
Annual Return
-25.1%
Cumulative gain past year
| Period | RMD Return | S&P 500 |
|---|---|---|
| 1m | -10.8% | +5.4% |
| 3m | -29.4% | +10.9% |
| 6m | -27.3% | +11.0% |
| 1y | -25.1% | +28.1% |
| ytd | -25.3% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RMD Fundamental Analysis
ResMed's revenue trajectory remains positive but shows signs of sequential deceleration; for the quarter ending December 31, 2025, revenue was $1.42 billion, representing a solid 10.98% year-over-year growth, however, this marks a slowdown from the 14.2% sequential growth seen in the prior quarter (Q1 revenue was $1.34 billion). Segment data indicates the core 'Sleep and Respiratory' hardware and consumables business, at $1.26 billion, is the primary growth driver, vastly outweighing the $166.9 million 'Residential Care Software' segment. The company is highly profitable with robust and expanding margins; net income for the latest quarter was $392.6 million, yielding a net margin of 27.59%, while the gross margin improved to 62.18%, up from 61.46% in the prior quarter, demonstrating strong pricing power and cost management. Operating income of $497.6 million resulted in an operating margin of 34.97%, which is healthy for the medical device industry and reflects the benefits of scaling its digital platform. The balance sheet is exceptionally strong with low financial risk, evidenced by a debt-to-equity ratio of only 0.14 and a high current ratio of 3.44, indicating ample liquidity. The company generates substantial cash flow, with free cash flow over the trailing twelve months at $1.79 billion, providing internal funding for growth initiatives, share repurchases, and dividends, as seen in the latest quarter's $175 million stock buyback and $87.6 million in dividends paid, supported by a return on equity of 23.47%.
Quarterly Revenue
$1.4B
2025-12
Revenue YoY Growth
+0.10%
YoY Comparison
Gross Margin
+0.62%
Latest Quarter
Free Cash Flow
$1.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RMD Overvalued?
Given ResMed's positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 27.02x, which is a significant premium to the forward PE of 15.62x, indicating the market expects a substantial rebound in earnings growth over the next twelve months, aligning with analyst EPS estimates averaging $16.15. Compared to industry averages, ResMed's trailing PE of 27.02x and Price-to-Sales ratio of 7.36x are elevated, suggesting the market has historically priced in its premium market position and growth profile, though the current discount to its own historical highs may reflect a recalibration of those expectations. Historically, the stock's own valuation has compressed from recent peaks; for instance, its PE ratio was 28.76x as of September 30, 2025, and has ranged higher in prior years, indicating the current multiple is at the lower end of its recent historical band, which could signal a value opportunity if fundamentals remain intact, but also reflects the market's concern over near-term growth prospects.
PE
27.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -90x~50x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: ResMed's primary financial risk is not leverage or liquidity—its balance sheet is pristine—but rather growth deceleration justifying its premium valuation. Revenue growth slowed to 10.98% YoY in Q2 from 14.2% sequentially, and a further slowdown could pressure the forward PE of 15.6x. While margins are expanding (gross margin to 62.18%), the company remains exposed to reimbursement changes in key markets like the Americas, which accounts for roughly two-thirds of revenue. Earnings volatility is low, but dependence on the Sleep & Respiratory Care segment (~89% of revenue) creates concentration risk if innovation stalls.
Market & Competitive Risks: The stock faces significant valuation compression risk, trading at a trailing PE of 27.02x and PS of 7.36x, premiums to the industry. If sector rotation away from healthcare staples persists, these multiples could contract further. Competitive disruption from new entrants or existing rivals in the sleep therapy market is a constant threat, potentially impacting market share and pricing power. The stock's low beta of 0.845 ironically highlights that its recent -22.25% YTD plunge is a company-specific issue, not a broad market move, suggesting internal or competitive concerns are driving the sell-off.
Worst-Case Scenario: The worst-case scenario involves a combination of accelerated revenue deceleration below 5%, margin contraction due to competitive pricing pressure, and a sector-wide de-rating of medical device stocks. This could trigger a wave of analyst downgrades and force the stock to re-rate towards its historical valuation floor. A realistic downside could see the stock fall to levels implied by a PE of 20x on the low-end EPS estimate of $15.93, or ~$318, but given the severe technical breakdown, a test of the 52-week low at $190.40 is immediate. A further 10-15% decline from that level is plausible in a panic sell-off, implying a total potential loss of 25-30% from the current $190.57 price.
FAQ
The key risks are: 1) Growth Deceleration: Revenue growth slowed to 10.98% YoY last quarter; further slowing could compress the valuation multiple. 2) Competitive/Market Risks: The company faces constant competition in sleep therapy and is exposed to reimbursement changes, particularly in the Americas (66% of revenue). 3) Technical & Sentiment Risk: The stock is at its 52-week low with a high short ratio of 9.7 days; a breakdown could trigger accelerated selling. 4) Valuation Compression: Elevated trailing multiples (PE 27x) leave the stock vulnerable if sector sentiment sours. The most severe near-term risk is the technical breakdown, while the most critical fundamental risk is sustained growth deceleration.
The 12-month forecast presents three scenarios. The Base Case (50% probability) sees the stock trading between $210 and $240 as growth stabilizes around 10% and margins hold. The Bull Case (30% probability) targets $260-$280 on re-accelerating growth and a sentiment reversal. The Bear Case (20% probability) warns of a drop to $170-$190 if growth slows further and technical support fails. The most likely outcome is the Base Case, assuming the company executes steadily in its structurally growing market. The key assumption is that ResMed can maintain its high profitability and low-double-digit revenue growth despite current headwinds.
RMD sends mixed valuation signals. It appears overvalued on a trailing basis with a PE of 27.02x and PS of 7.36x, which are premiums to the industry. However, the forward PE of 15.62x, based on analyst EPS estimates of $16.15, suggests the market expects significant earnings growth and prices the stock at a more reasonable level. Compared to its own historical valuation, the current multiple is at the lower end of its recent range. Overall, the stock is fairly valued to slightly undervalued based on forward earnings, but this valuation is justified only if the company meets its growth targets. The market is paying a fair price for expected, but not guaranteed, future growth.
RMD is a complex buy at current levels. For value-oriented, long-term investors, the combination of a forward PE of 15.6x, a 27.6% net margin, and a pristine balance sheet is compelling following a 22% YTD decline. The implied upside to a base-case target of $210-$240 is 10-26%. However, the severe negative momentum and risk of further technical breakdown make it a 'falling knife' scenario for short-term traders. It is a good buy for patient investors who believe the fundamental story remains intact and are willing to average in, but not for those seeking immediate gains or with low risk tolerance.
RMD is unequivocally more suitable for a long-term investment horizon. The company's business model—serving a chronic condition with recurring revenue—and its financial strength support a multi-year holding period. Its low dividend yield (0.82%) and current high volatility (despite a low beta of 0.845) make it a poor choice for income seekers or short-term traders trying to catch the bottom. Given the deep technical damage and need for the fundamental story to reaffirm itself, investors should be prepared to hold for a minimum of 2-3 years to allow the operational performance to overcome near-term sentiment and price volatility.